Abstract
Gliomas are common primary brain tumors in adults. This high degree of glioma malignancy is characterized by a disappointing outlook, despite the modern approaches to treatment. Therefore cases of prolonged relapse-free period of the disease, as well as treatment regimen and control regimen concerning gliomas with high degree of anaplasia are of exceptional interest. Even more exceptionally interesting is the drug bevacizumab, which in our clinical practice allowed to provide the patient with the diseasefree high-grade glioma from 2012 year to the present.
Highlights
Wherein high-grade anaplasia glioma is characterized by disappointing prognosis
follow-up concerning gliomas with high degree of anaplasia are of exceptional interest
which in our clinical practice allowed to provide the patient with high-grade glioma the disease-free period from 2012 year
Summary
Own investigations к различным методам лечения и высокая вероятность рецидива вследствие неконтролируемой клеточной пролиферации, дисрегуляции апоптоза, выраженной опухолевой инвазии, микрососудистой пролиферации, наличия молекулярных маркеров опухоли [23, 24, 25, 26]. Впервые данные о возможной эффективности бевацизумаба при глиомах высокой степени злокачественности опубликовал V. В результате было выявлено, что индивидуальное использование бевацизумаба для лечения рецидивирующих глиом увеличивает частоту объективного ответа и 6-месячную безрецидивную выживаемость (PFS) (RR 2,36 95% CI 1,46–3,82; p
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.